Schreiner MediPharm, Ypsomed push self-medication adherence with NFC label

Schreiner MediPharm and Swiss-based Ypsomed have developed an NFC label that is applied to the YpsoMate autoinjector to assist in the self-administration of medicines to better comply with prescribed therapies.

Schreiner MediPharm, Ypsomed provide self-medication adherence with NFC label

YpsoMate is an autoinjector for self-medication of a wide range of pharmaceutical substances and in a diverse range of therapeutic areas. To turn this injection platform into a smart device, Ypsomed developed SmartPilot as a reusable add-on with embedded sensor technology. The autoinjector is pushed into SmartPilot and is automatically recognized due to the NFC label applied to the injection aid. The information about the medication stored on the NFC chip is transmitted via SmartPilot to a related smartphone app via Bluetooth connection.

The resulting connected device enhances the safety of patients and assists them in the self-administration of medicines to better comply with prescribed therapies.

The technology behind this connected device is the interlinking of diverse sensors and the label with an integrated NFC chip, which Schreiner MediPharm adapted for YpsoMate. The NFC chip identifies and authenticates the medicine and checks its expiration date. According to the prescribed therapy, the patient can be guided in real time through the injection process by means of the SmartPilot sensors, and feedback on the correct administration of the medicine can be transmitted. It is also possible to store the entire injection history in detail – from injection time and success through to patient well-being — and to share it with other stakeholders. The attending physician, for instance, is then able to use this information to adjust the continuing therapy plan.

Arne Rehm, product manager, RFID/NFC solutions at Schreiner MediPharm, commented: ‘The integration of NFC technology, which has to ensure reliable reading, in a very small space posed the primary challenge in this label development. Subsequent ease of processing was another specified objective.’

Andreas Schneider, innovation and business development manager at Ypsomed, added: ‘The cooperation between Ypsomed and Schreiner MediPharm yielded an innovative and complete solution for pharmaceutical manufacturers, who are now able to provide patients with SmartPilot, a valuable tool supporting them in self-medication efforts.’